New schizophrenia drug enters first human trials
Symptom relief
Recruiting now
This early-phase study tests a new oral drug, NTX-253, in healthy adults and people with stable schizophrenia. The main goal is to check safety and how the body processes the drug. About 73 participants will take single or multiple doses to find the right dose range.
Phase: EARLY_PHASE1 • Sponsor: Neurosterix • Aim: Symptom relief
Last updated May 17, 2026 04:29 UTC